Preventing breast Ca with aromatase inhibitors

Contemporary Ob/Gyn

Volumn 48, Issue 12, 2003, Pages 68-80

  Mitwally, Mohamed F ^a   Casper, Robert F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 55249126341     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem. 1990; 33:2933-2942.
2. Akhtar M, Njar VC, Wright JN. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J SteroidBiochem Mol Biol. 1993;44:375-387.
3. Santen RJ, Manni A, Harvey H, et al. Endocrine treatment of breast cancer in women. Endocr Rev. 1990;11:221-265.
4. Lonning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol. 1996;35:38-43.
5. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620-2635.
6. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881-894.
7. Brueggemeier RW. Aromatase inhibitors: mechanisms of steroidal inhibitors. Breast Cancer Res Treat 1994;30:31-42.
8. Vanden Bossche HV, Moereels H, Koymans LM. Aromatase inhibitors: mechanisms for non-steroidal inhibitors. Breast Cancer Res Treat. 1994;30:43-55.
9. Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. JAMA. 1974;230:1661-1665.
10. Lipton A, Santen RJ. Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer. 1974;33:503-512.
11. Newsome HH, Brown PW, Terz JJ, et al. Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer. 1977;39:542-546.
12. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment oh the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002;20:3317-3327.
13. Marty M, Gershanovich M, Campos B, et al. Letrozole, a new potent, selective aromatase inhibitor (AT) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens. Proceedings of the American Society of Clinical Oncology. 1997;16:156a. Abstract 544.
14. Dowsett M. Biological background to aromatase inhibition. The Breast. 1996 5:196-201.
15. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104-107.
16. Muss HB, Case ID, Atkins JN, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994;12:1630-1638.
17. Kellokumpu-Lehtinen P, Huovinen R, Johansson R. Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate. Cancer. 1987;60:2376-2381.
18. Gale KE, Andersen JW, Tormey DC, et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994;73:354-361.
19. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
20. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
21. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154:2585-2588.
22. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003;91:154-159.
23. Tamoxifen and endometrial cancer. ACOG Committee Opinion. No. 232. Washington, D.C.: American College of Obstetricians and Gynecologists, 2000.
24. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
25. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-2442.
26. Sinha S, Kaseta J, Santner SJ, et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat. 1998;48:45-51.
27. Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer. 1990;62:679-683.
28. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-2606.
29. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758-3767.
30. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748-3757.
31. Hamilton A, Piccart M. The third-generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol. 1999;10:377-384.
32. Cheung KL, Howell A, Robertson JF. Preoperative endocrine therapy for breast cancer. Endocr Relat Cancer. 2000;7:131-141.
33. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001; 2:561-570.
34. Forrest AP, Levack PA, Chetty U, et al. A human tumour model. Lancet. 1986;2:840-842.
35. Dixon JM, Neoadjuvant endocrine therapy. In: Miller WR, Santen RJ, eds. Aromatase Inhibition and Breast Cancer. New York: Marcel Dekker, 2001:103-116.
36. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. 2002;9:9-15.
37. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph-node negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
38. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
39. Coombes RC, Powles TJ, Easton D, et al. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res. 1987;47: 2494-2497.
40. Jones AL, Powles TJ, Lav; M, et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol. 1992;10:1547-1552.
41. Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol. 2001;19:4209-4215.
42. Baum M, Budzar AV, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
43. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J. Med. 2003;349:1793-1802.
44. Bryant J, Wolmark N. Letrozole after tamoxifen for breast cancer-What is the price of success? W Engl J Med. 2003;349:1855-1857.
45. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I.: a randomised prevention trial). Lancet. 2002;360:817-824.
46. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J Natl Cancer Inst. 1996;88:1529-1542.
47. Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9:236-241.